Cipla's European subsidiary Cipla EU completed the acquisition of an additional stake in Cipla Maroc SA, Morocco, a joint venture company.

Cipla EU acquired an additional 15.1 percent of Cipla Maroc SA, Morocco shares from the The Pharmaceutical Institute (PHI) for MAD 81.1 million or around USD 8.05 million.

Accordingly, Cipla EU will now hold a 75.10 percent stake in the joint venture company, and the remaining 24.90 percent stake will be held by Societe Marocaine de Cooperation Pharmaceutique (Cooper Pharma).